Quick Answer
BridgeBio Oncology Therapeutics, Inc. reported Net Income Loss of -$134.04 million for the year ending 2025.
- BridgeBio Oncology Therapeutics, Inc. showed a decrease of -80.5% in Net Income Loss from 2024 to 2025.
- This data is from BridgeBio Oncology Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: -$15.44 million | Q2 2024: -$21.82 million | Q3 2024: -$17.32 million | Q1 2025: -$22.06 million | Q2 2025: -$28.44 million | Q3 2025: -$44.76 million.
- Over the full 3 years of available data (2023 to 2025), BridgeBio Oncology Therapeutics, Inc.'s Net Income Loss has declined by 321,410.1%.
- Historical annual values: Fiscal year 2025: -$134.04 million | Fiscal year 2024: -$74.28 million | Fiscal year 2023: -$41.7 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: